ClinicalTrials.Veeva

Menu

Prospective Registry for Assessment of Acute Ischemic Stroke Patients Treated With Neurothrombectomy Devices in India (PRAAN)

Medtronic logo

Medtronic

Status

Completed

Conditions

Acute Ischemic Stroke

Treatments

Device: Neurothrombectomy

Study type

Observational

Funder types

Industry

Identifiers

NCT05005962
MDT20026

Details and patient eligibility

About

PRAAN is a post-market registry designed to collect real-world data associated with the use of Medtronic market release neurothrombectomy devices in acute ischemic stroke (AIS) patients from India.

Full description

The objective of this registry is to access clinical outcomes associated with the use of these device in patients experiencing the AIS due to large intracranial vessel occlusion within 8 hours of last known well.

Real-world evidence per Standard-of-care (SOC) will be generated using Medtronic neurothrombectomy devices approved in India, using on-label indications for use in this post-market clinical follow-up registry.

Enrollment

200 patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  1. Subject/subject's legally authorized representative has given Informed Consent according to country regulations, and/or EC requirements

  2. Subject is 18 years of age or older

  3. Subject has experienced an Acute Ischemic Stroke due to large intracranial vessel occlusion in at least one of the following intracranial vessels: internal carotid artery (ICA), M1 and M2 segments of the middle cerebral artery (MCA), basilar, and vertebral arteries

  4. Subject has been or will be treated with a Medtronic market-released neuro thrombectomy device as the initial device used to remove the thrombus

  5. Subject is willing to participate in a 90-day follow-up visit

  6. Treatment within 24 hours of last known well. For subjects with stroke onset >6 hours:

    • ASPECTS score >5 (per DW-MRI) or >6 (per NCCT)
    • NCCT Core Infarct < 70 ml or MRI DWI with < 70 ml core volume or CTP Ratio of volume of ischemic tissue (penumbra) to infarction of ≥1.8 and an absolute volume of potentially reversible ischemia of ≥15ml
  7. Pre-Stroke Modified Rankin Scale (mRS) score ≤1 (immediately) prior to stroke onset

  8. Pre-treatment National Institutes of Health Stroke Scale (NIHSS)

    • ≥6 and ≤30 for patients with ≤6 hours of stroke onset.
    • ≥10 and ≤30 for patients with >6 hours of stroke onset.

Exclusion criteria

  1. Concurrent participation in another mechanical neurothrombectomy device trial or any other clinical trial with an active treatment arm or where the study procedure or treatment might confound the study analysis
  2. Patients meeting the contraindication as mentioned in the IFU of devices.
  3. Significant mass effect with midline shift

Trial design

200 participants in 1 patient group

Acute ischemic patients suffering with stroke
Description:
Acute ischemic patients treated with commercially available neurothrombectomy devices in India. The device can be either a stent retriever or aspiration catheter to treat the stroke as per the labeling indications of the products.
Treatment:
Device: Neurothrombectomy

Trial contacts and locations

14

Loading...

Central trial contact

Rajneesh Randhawa, MSc; Vinay Rajan, Ph.D

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems